Retatrutide

Overview

Retatrutide (LY3437943) is an investigational compound: it has not been approved by the FDA or any other regulatory agency for any use, and it remains in clinical development. It is described in the literature as a single 39-amino-acid peptide, modified with a fatty-acid side chain, that acts as an agonist at three receptors: GIP, GLP-1, and glucagon. It is studied in metabolic-regulation, energy-balance, and body-composition research, where its combined activity at the three receptors is compared with that of single- and dual-receptor agonists. The published findings come from preclinical models and from clinical trials that are still under way, so longer-term data remain incomplete. It is offered here for research use only.

Research highlights

• An investigational compound, not approved by the FDA or any other regulatory agency
• Described as a single 39-amino-acid peptide with a fatty-acid side chain
• Studied for its role at GIP, GLP-1, and glucagon receptors
• Investigated in models of metabolic regulation and energy balance
• Explored in body-composition research, with longer-term data still incomplete